New hope for kids with lupus: drug combo shows promise in chinese trial
NCT ID NCT04908865
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study looked at whether adding belimumab to standard treatment is safe and works for Chinese children (ages 5-17) with active lupus. Over 52 weeks, researchers tracked side effects and disease activity using a standard lupus score. The goal was to see if the drug combination could better control the disease without causing serious harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Beijing, 100045, China
-
GSK Investigational Site
Changchun, 130021, China
-
GSK Investigational Site
Changsha, 410007, China
-
GSK Investigational Site
Chongqing, 400014, China
-
GSK Investigational Site
Hangzhou, 310052, China
-
GSK Investigational Site
Nanjing, 210011, China
-
GSK Investigational Site
Shanghai, 361006, China
-
GSK Investigational Site
Suzhou, 215007, China
-
GSK Investigational Site
Xi'an, 710054, China
Conditions
Explore the condition pages connected to this study.